Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Mayne Pharma Group ( (AU:MYX) ) is now available.
Mayne Pharma Group Limited has announced a scheme of arrangement where Cosette Pharmaceuticals, Inc. will acquire 100% of its shares. The directors of Mayne Pharma unanimously recommend shareholders vote in favor of the scheme, highlighting its alignment with shareholder interests, barring any superior proposals. The scheme meeting will allow shareholders to vote, and results will be announced shortly after.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$7.09 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercializing novel pharmaceuticals to offer patients better, safe, and more accessible medicines. The company is a leader in dermatology and women’s health and provides contract development and manufacturing services globally. With a 40-year track record, Mayne Pharma has successfully commercialized numerous products worldwide through innovative oral drug delivery systems.
Average Trading Volume: 962,966
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$412.7M
Find detailed analytics on MYX stock on TipRanks’ Stock Analysis page.